NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

Well, yeah, and the exclusion of "recurrent" kind of made it nebulous (because rapids are recurrent), yet the CEO, if I recall, said he did not think they excluded rapids, but he also admitted not knowing why they exactly chose to go after the antigens that ICT-107 targeted. So....it's hard to say. Now in their new trial, they screened something like 230 but randomized only 11, so they need to change their screening requirements.